Comprehensive Analysis and Identification of an Immune-Related Gene Signature with Prognostic Value for Prostate Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Herden J, Heidenreich A, Weissbach L. Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer? BJU Int. 2017;120(2):212–218. doi:10.1111/bju.13715
   PubMed Web of Science ®Google Scholar
• Caster JM, Falchook AD, Hendrix LH, Chen RC. Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on Biopsy Gleason Score and PSA: a Population-Based Study of Modern Patients. Int J Radiat Oncol Biol Phys. 2015;92(2):244–251. doi:10.1016/j.ijrobp.2015.01.051
   PubMed Web of Science ®Google Scholar
• Dimakakos A, Armakolas A, Koutsilieris M. Novel tools for prostate cancer prognosis, diagnosis, and follow-up. Biomed Res Int. 2014;2014:890697. doi:10.1155/2014/890697
   PubMed Web of Science ®Google Scholar
• Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25. doi:10.1038/nrurol.2016.175
   PubMed Web of Science ®Google Scholar
• Cho IC, Kwon WA, Kim JE, et al. Prostate volume has prognostic value only in pathologic T2 radical prostatectomy specimens. J Korean Med Sci. 2011;26(6):807–813. doi:10.3346/jkms.2011.26.6.807
   PubMed Web of Science ®Google Scholar
• Westdorp H, Skold AE, Snijer BA, et al. Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol. 2014;5:191. doi:10.3389/fimmu.2014.00191
   PubMed Web of Science ®Google Scholar
• Bostwick DG, de la Roza G, Dundore P, Corica FA, Iczkowski KA. Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate. 2003;55(3):187–193. doi:10.1002/pros.10224
   PubMed Web of Science ®Google Scholar
• Russo JW, Balk SP. Initiation and evolution of early onset prostate cancer. Cancer Cell. 2018;34(6):874–876. doi:10.1016/j.ccell.2018.11.010
   PubMed Web of Science ®Google Scholar
• Tyekucheva S, Bowden M, Bango C, et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017;8(1):420. doi:10.1038/s41467-017-00460-4
   PubMed Web of Science ®Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322. doi:10.1016/j.ccr.2012.02.022
   PubMed Web of Science ®Google Scholar
• Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174–186. doi:10.1038/s41568-019-0238-1
   PubMed Web of Science ®Google Scholar
• Kim MG, Shon Y, Kim J, Oh YK. Selective activation of anticancer chemotherapy by cancer-associated fibroblasts in the tumor microenvironment. J Natl Cancer Inst. 2017;109(1):djw186. doi:10.1093/jnci/djw186
   PubMedGoogle Scholar
• Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423–1429. doi:10.2967/jnumed.118.210435
   PubMed Web of Science ®Google Scholar
• Di Donato M, Zamagni A, Galasso G, et al. The androgen receptor/filamin A complex as a target in prostate cancer microenvironment. Cell Death Dis. 2021;12(1):127. doi:10.1038/s41419-021-03402-7
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Sun S, Guo W, Wang Z, et al. Development and validation of an immune-related prognostic signature in lung adenocarcinoma. Cancer Med. 2020;9(16):5960–5975. doi:10.1002/cam4.3240
   PubMed Web of Science ®Google Scholar
• Du GW, Yan X, Chen Z, et al. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC). Aging (Albany N Y). 2020;12(9):8484–8505.
   PubMedGoogle Scholar
• Li F, Guo H, Wang Y, Liu B, Zhou H. Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer. Int Immunopharmacol. 2020;85:106641. doi:10.1016/j.intimp.2020.106641
   PubMed Web of Science ®Google Scholar
• Zhao X, Hu D, Li J, Zhao G, Tang W, Cheng H. Database mining of genes of prognostic value for the prostate adenocarcinoma microenvironment using the cancer gene atlas. Biomed Res Int. 2020;2020:5019793.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Yuan Y, Xu Y, Xu J, Ball RL, Liang H. Predicting the lethal phenotype of the knockout mouse by integrating comprehensive genomic data. Bioinformatics. 2012;28(9):1246–1252. doi:10.1093/bioinformatics/bts120
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–273. doi:10.1038/ng1180
   PubMed Web of Science ®Google Scholar
• Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017;6. doi:10.7554/eLife.26476
   PubMed Web of Science ®Google Scholar
• Chen J, Guo XZ, Li HY, Zhao JJ, Xu WD. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro. World J Gastroenterol. 2017;23(5):817–829. doi:10.3748/wjg.v23.i5.817
   PubMed Web of Science ®Google Scholar
• Sun T, Patil R, Galstyan A, et al. Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment cross-talk. Cancer Res. 2019;79(6):1239–1251. doi:10.1158/0008-5472.CAN-18-2725
   PubMed Web of Science ®Google Scholar
• Ren B, Cui M, Yang G, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1). doi:10.1186/s12943-018-0858-1
   Web of Science ®Google Scholar
• Zhang G, Lu J, Yang M, Wang Y, Liu H, Xu C. Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer. Cancer Immunol Immunother. 2020;69(2):175–187. doi:10.1007/s00262-019-02454-1
   PubMed Web of Science ®Google Scholar
• Woo JR, Liss MA, Muldong MT, et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 2014;12:30. doi:10.1186/1479-5876-12-30
   PubMed Web of Science ®Google Scholar
• Shen T, Li Y, Zhu S, et al. YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression. J Exp Clin Cancer Res. 2020;39(1):36. doi:10.1186/s13046-020-1542-z
   PubMed Web of Science ®Google Scholar
• Pertega-Gomes N, Vizcaino JR, Attig J, Jurmeister S, Lopes C, Baltazar F. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer. 2014;14:352. doi:10.1186/1471-2407-14-352
   PubMed Web of Science ®Google Scholar
• Watanabe M, Kanao K, Suzuki S, et al. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis. Prostate. 2019;79(14):1658–1665. doi:10.1002/pros.23890
   PubMed Web of Science ®Google Scholar
• Erlandsson A, Carlsson J, Lundholm M, et al. M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate. 2019;79(4):363–369. doi:10.1002/pros.23742
   PubMed Web of Science ®Google Scholar
• Adekoya TO, Richardson RM. Cytokines and chemokines as mediators of prostate cancer metastasis. Int J Mol Sci. 2020;21(12):4449. doi:10.3390/ijms21124449
   PubMed Web of Science ®Google Scholar
• Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4(1):11–22. doi:10.1038/nrc1252
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.49
   PubMed Web of Science ®Google Scholar
• Tone K, Stappers MHT, Willment JA, Brown GD. C-type lectin receptors of the Dectin-1 cluster: physiological roles and involvement in disease. Eur J Immunol. 2019;49(12):2127–2133. doi:10.1002/eji.201847536
   PubMed Web of Science ®Google Scholar
• Daley D, Mani VR, Mohan N, et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat Med. 2017;23(5):556–567. doi:10.1038/nm.4314
   PubMed Web of Science ®Google Scholar
• Alaeddine M, Prat M, Poinsot V, et al. IL13-mediated Dectin-1 and mannose receptor overexpression promotes macrophage antitumor activities through recognition of sialylated tumor cells. Cancer Immunol Res. 2019;7(2):321–334. doi:10.1158/2326-6066.CIR-18-0213
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chu X, Chen J, et al. Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. Nat Commun. 2016;7:12368. doi:10.1038/ncomms12368
   PubMed Web of Science ®Google Scholar
• Shen L, Yang M, Lin Q, Zhang Z, Zhu B, Miao C. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep. 2016;36(2):877–885. doi:10.3892/or.2016.4869
   PubMed Web of Science ®Google Scholar
• Fischer H, Stenling R, Rubio C, Lindblom A. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 2001;22(6):875–878. doi:10.1093/carcin/22.6.875
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang C, Yang X, et al. Cytoplasmic collagen XIalphaI as a prognostic biomarker in esophageal squamous cell carcinoma. Cancer Biol Ther. 2018;19(5):364–372. doi:10.1080/15384047.2018.1423915
   PubMed Web of Science ®Google Scholar
• Sun D, Jin H, Zhang J, Tan X. Integrated whole genome microarray analysis and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as predictive biomarkers for pancreatic cancer. Cancer Cell Int. 2018;18:174. doi:10.1186/s12935-018-0669-x
   PubMed Web of Science ®Google Scholar
• Wu YH, Chang TH, Huang YF, Huang HD, Chou CY. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene. 2014;33(26):3432–3440. doi:10.1038/onc.2013.307
   PubMed Web of Science ®Google Scholar
• Toss MS, Miligy IM, Gorringe KL, et al. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Mod Pathol. 2019;32(10):1460–1472. doi:10.1038/s41379-019-0286-9
   PubMed Web of Science ®Google Scholar